DMAC long strategyA analysis of DMAC in a multi-year chart run to see if market downward pressure is substantial enough overshadow the upcoming catalyst for DMAC in the coming weeks.
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
See all ideas
DiaMedica Therapeutics slips 32% in the first three hours of Tuesday trading despite encouraging results out of its latest chronic kidney disease trial.
See all events